Bio­gen's Alzheimer's drug ad­u­canum­ab im­plodes in a PhI­II dis­as­ter — putting them at a per­ilous cross­roads

Bio­gen’s big late-stage play in Alzheimer’s has just crashed. And the dam­age will be ex­ten­sive.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.